| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |